Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #4 of 83 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Senores Pharmaceuticals targets robust growth in FY’27 and beyond, building on 50% growth guidance for FY’26. The company has recorded 100% PAT growth for two consecutive years but considers repeating this level in FY’27 as "a little asking too much" due to the higher base (INR650+ crores PAT expected this year).
From Senores Pharmaceuticals Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Senores Pharmaceuticals targets robust growth in FY’27 and beyond, building on 50% growth guidance for FY’26.
- The company expects to leverage Apnar acquisition and product launches (28 approved, 22 in development) to drive growth over the next 6-8 quarters.
- Regulated market revenue mix is expected to shift towards 65% own products by FY’27, improving realizations and margins.
- Emerging market business to continue growing with 56 product commercializations underway, driving revenue from distributor-led and export models.
- Branded generics in India forecasted to grow significantly, with projected revenues of INR40-50 crores in FY’26 and INR80+ crores next year.
2 more points from Senores Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Senores Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex for the next 2-3 years is expected to be around INR 50 crores to INR 100 crores, depending on the requirement. (Page 16)
- Earlier planned capex in the US is now partly substituted due to the acquisition of Apnar Pharmaceuticals, providing extended capacity. (Page 15-16)
- Expansion of the Atlanta Oral Solid Facility from 1 billion to 2 billion tablets is targeted to be completed by next year. (Page 15)
- Apnar acquisition adds manufacturing capacity in India, enabling shift of some low-margin products from the US to India, optimizing facility utilization and margin profiles. (Page 15)
2 more points from Senores Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Senores Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Swapnil Shah mentions that the company will keep updating the investor community on development sets and orders regularly.
- The company is closely monitoring facility utilization and transitions of products from the US to India to optimize margins and capacity.
- They have a strong product pipeline with 28 approved ANDAs yet to be launched over the next 6 to 8 quarters and 22 under development.
2 more points from Senores Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Senores Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹192 Cr, net profit ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Senores Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn Ltd (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharmaceuticals Ltd (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Senores Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Senores Pharmaceuticals Ltd Q3 FY26 results?
Senores Pharmaceuticals targets robust growth in FY’27 and beyond, building on 50% growth guidance for FY’26. The company has recorded 100% PAT growth for two consecutive years but considers repeating this level in FY’27 as "a little asking too much" due to the higher base (INR650+ crores PAT expected this year).
What is Senores Pharmaceuticals Ltd share price analysis?
Senores Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 53.9 with a market cap of ₹6,805 Cr. Investors should review the full earnings analysis for detailed insights.
Is Senores Pharmaceuticals Ltd planning capital expenditure?
Capex for the next 2-3 years is expected to be around INR 50 crores to INR 100 crores, depending on the requirement.
Keep Senores Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.